Kazia Therapeutics Limited(KZIA)Earnings, Financials & Key Ratios
KZIA•NASDAQ
Price updated Jun 11, 2026
AboutKazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Show more
- Revenue$42K-98.2%
- EBITDA-$13M+50.1%
- Net Income-$21M+22.7%
- EPS (Diluted)-18.90+65.6%
- Gross Margin100%
- EBITDA Margin-31626.19%-2644.8%
- Operating Margin-33850%-2644.9%
- Net Margin-49290.48%-4148.4%
KZIA Key Insights
Kazia Therapeutics Limited (KZIA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 46.8% over 5 years
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KZIA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KZIA Price & Volume
Kazia Therapeutics Limited (KZIA) stock price & volume — 10-year historical chart
Loading chart...
KZIA Growth Metrics
Kazia Therapeutics Limited (KZIA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.23%
5 Years-46.83%
3 Years61.34%
TTM22836.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-3.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.2%
Return on Capital
10 Years-82.87%
5 Years-132.34%
3 Years-223.1%
Last Year-
KZIA Peer Comparison
Kazia Therapeutics Limited (KZIA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 SNDX | 1.58B | 17.91 | -5.44 | 6.28% | -112.01% | -256.66% | 5.36 | |
 AGIO | 1.71B | 28.72 | -4.03 | 48.03% | -6.4% | -34.11% | 0.05 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 IDYA | 2.53B | 28.84 | -22.53 | 30.24% | -62.17% | -13.96% | 0.03 | |
 NUVL | 9.08B | 123.45 | -21.10 | -42.78% |
Compare KZIA vs Peers
Kazia Therapeutics Limited (KZIA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KZIA Income Statement
Kazia Therapeutics Limited (KZIA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 8.79M | 13.11K | 1.56K | 988.11K | 15.18M | 10K | 555 | 2.31M | 42K |
Revenue Growth % | 115.87% | -99.85% | -88.06% | 63038.02% | 1436.57% | -99.93% | -94.45% | 415755.86% | -98.18% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 8.79M▲ 0% | 13.11K▼ 99.9% | 1.56K▼ 88.1% | 988.11K▲ 63038.0% | 15.18M▲ 1436.6% | 10K▼ 99.9% | 555▼ 94.5% | 2.31M▲ 415755.9% | 42K▼ 98.2% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
Gross Profit Growth % | 115.87% | -99.85% | -88.06% | 63038.02% | 1436.57% | -99.93% | -94.45% | 415755.86% | -98.18% |
Operating Expenses | 19.66M | 14.69M | 10.25M | 13.18M | 21.56M | 25.41M | 24.12M | 30.77M | 14.26M |
OpEx % of Revenue | 223.67% | 112046.08% | 655143.77% | 1334.28% | 141.99% | 254090% | 4346761.08% | 1333.19% | 33950% |
Selling, General & Admin | 8.53M | 5.6M | 3.79M | 3.69M | 7.02M | 5.24M | 8.58M | 13.56M | 8.72M |
SG&A % of Revenue | 97.05% | 42706.74% | 241916.93% | 373.43% | 46.24% | 52400% | 1546488.65% | 587.65% | 20761.9% |
Research & Development | 11.14M | 9.77M | 6.48M | 9.49M | 14.54M | 20.17M | 15.56M | 17.38M | 7.33M |
R&D % of Revenue | 126.72% | 74565.15% | 413801.92% | 960.86% | 95.77% | 201690% | 2804336.94% | 753.03% | 17442.86% |
Other Operating Expenses | 0 | 3.67M | -9K | 0 | -2K | 0 | -22.56K | -173K | -1.79M |
Operating Income | -10.85M▲ 0% | -12.49M▼ 15.1% | -8.38M▲ 32.9% | -12.2M▼ 45.5% | -6.38M▲ 47.7% | -25.4M▼ 298.4% | -24.12M▲ 5.0% | -28.46M▼ 18.0% | -14.22M▲ 50.0% |
Operating Margin % | -123.49% | -95262.44% | -535463.26% | -1234.28% | -41.99% | -253990% | -4346661.08% | -1233.19% | -33850% |
Operating Income Growth % | 15.02% | -15.06% | 32.89% | -45.54% | 47.72% | -298.35% | 5.02% | -17.98% | 50.05% |
EBITDA | -9.44M | -10.94M | -7.3M | -11.11M | -5.11M | -23.53M | -22.25M | -26.59M | -13.28M |
EBITDA Margin % | -107.4% | -83475.74% | -466198.08% | -1124.54% | -33.66% | -235300% | -4009821.44% | -1152.21% | -31626.19% |
EBITDA Growth % | 22.18% | -15.93% | 33.32% | -52.3% | 54% | -360.38% | 5.42% | -19.49% | 50.05% |
D&A (Non-Cash Add-back) | 1.41M | 1.54M | 1.08M | 1.08M | 1.26M | 1.87M | 1.87M | 1.87M | 934K |
EBIT | -10.85M | -14.57M | -8.79M | -12.19M | -6.38M | -25.38M | -24.15M | -28.46M | -14.22M |
Net Interest Income | 0 | 0 | -2.09M | 66K | 42.24K | 0 | 22.84K | 12K | 72K |
Interest Income | 276 | 119K | 100K | 66K | 42.24K | 2.09K | 22.84K | 12K | 72K |
Interest Expense | 0 | 0 | 2.19M | 0 | 0 | 2.09K | 0 | 0 | 0 |
Other Income/Expense | 7.87K | 6.02M | -1.75M | -569.58K | -2.53M | 17K | 3.41M | 1.41M | -8.23M |
Pretax Income | -10.87M▲ 0% | -6.34M▲ 41.6% | -10.57M▼ 66.6% | -12.77M▼ 20.8% | -8.9M▲ 30.3% | -25.38M▼ 185.1% | -20.74M▲ 18.3% | -27.05M▼ 30.4% | -22.45M▲ 17.0% |
Pretax Margin % | -123.68% | -48397.92% | -675271.57% | -1291.93% | -58.64% | -253820% | -3736265.23% | -1171.97% | -53447.62% |
Income Tax | -198.54K | -305K | -298K | -298.19K | -484K | -368K | -271.09K | -271K | -1.75M |
Effective Tax Rate % | 1.83% | 4.81% | 2.82% | 2.34% | 5.44% | 1.45% | 1.31% | 1% | 7.78% |
Net Income | -10.67M▲ 0% | -6.04M▲ 43.4% | -10.27M▼ 70.1% | -12.47M▼ 21.4% | -8.42M▲ 32.5% | -25.01M▼ 197.1% | -20.47M▲ 18.2% | -26.78M▼ 30.8% | -20.7M▲ 22.7% |
Net Margin % | -121.42% | -46071.1% | -656230.03% | -1261.75% | -55.46% | -250140% | -3687419.82% | -1160.23% | -49290.48% |
Net Income Growth % | 11.54% | 43.4% | -70.06% | -21.4% | 32.46% | -197.08% | 18.19% | -30.85% | 22.69% |
Net Income (Continuing) | -10.67M | -6.04M | -10.27M | -12.47M | -8.42M | -25.01M | -20.47M | -26.78M | -20.7M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -109.30▲ 0% | -59.80▲ 45.3% | -85.60▼ 43.1% | -80.00▲ 6.5% | -35.80▲ 55.3% | -95.00▼ 165.4% | -55.00▲ 42.1% | -55.00▲ 0.0% | -18.90▲ 65.6% |
EPS Growth % | 19.16% | 45.29% | -43.14% | 6.54% | 55.25% | -165.36% | 42.11% | 0% | 65.64% |
EPS (Basic) | -109.30 | -59.80 | -85.60 | -80.00 | -35.80 | -95.00 | -55.00 | -55.00 | -18.90 |
Diluted Shares Outstanding | 97.63K | 100.96K | 120.01K | 152.46K | 235.4K | 265K | 368.6K | 479.6K | 1.1M |
Basic Shares Outstanding | 97.63K | 100.96K | 120.01K | 152.46K | 235.4K | 265K | 368.6K | 479.6K | 1.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KZIA Balance Sheet
Kazia Therapeutics Limited (KZIA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.48M | 9.26M | 7.54M | 10.65M | 29.39M | 9.45M | 10.77M | 6.14M | 4.93M |
Cash & Short-Term Investments | 14.45M | 5.96M | 5.45M | 8.76M | 27.59M | 7.36M | 5.24M | 1.66M | 4.34M |
Cash Only | 14.45M | 5.96M | 5.43M | 8.76M | 27.59M | 7.36M | 5.24M | 1.66M | 4.34M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 5.07K | 1.13K | 1.56M | 439 | 0 | 51K | 105K | 133K | 90K |
Days Sales Outstanding | 0.21 | 31.47 | 363.27K | 0.16 | - | 1.86K | 69.05K | 21.03 | 782.14 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 4.26M | 0 | 159.45K | 1.19M | 84.36K | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 16.43M | 18.91M | 13.66M | 12.41M | 28.7M | 26.44M | 17.31M | 15.44M | 1.13M |
Property, Plant & Equipment | 489.61K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | 17.95x | 13.11x | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 15.92M | 14.58M | 13.49M | 12.41M | 22M | 19.14M | 17.27M | 15.4M | 1.09M |
Long-Term Investments | 21.8K | 4.33M | 168.43K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -16.43M | -18.92M | 0 | 0 | 6.69M | 7.3M | 43K | 40K | 40K |
Total Assets | 35.91M▲ 0% | 28.18M▼ 21.5% | 21.18M▼ 24.8% | 23.06M▲ 8.9% | 58.09M▲ 151.9% | 35.89M▼ 38.2% | 28.08M▼ 21.7% | 21.59M▼ 23.1% | 6.06M▼ 71.9% |
Asset Turnover | 0.24x | 0.00x | 0.00x | 0.04x | 0.26x | 0.00x | 0.00x | 0.11x | 0.01x |
Asset Growth % | 1.11% | -21.54% | -24.84% | 8.91% | 151.86% | -38.22% | -21.75% | -23.14% | -71.92% |
Total Current Liabilities | 5.38M | 3.89M | 2.21M | 5.07M | 8.33M | 6.73M | 7.57M | 25.8M | 14.05M |
Accounts Payable | 1.25M | 1.41M | 1.05M | 1.69M | 1.89M | 1.52M | 857K | 4.55M | 5.64M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.84M | 1.8M | 634K | 396K |
Deferred Revenue (Current) | 41K | 138K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.36M | 1.68M | 716.64K | 1.58M | 3.16M | 1.13M | 1.44M | 10.1M | 3.54M |
Current Ratio | 3.62x | 2.38x | 3.42x | 2.10x | 3.53x | 1.40x | 1.42x | 0.24x | 0.35x |
Quick Ratio | 3.62x | 2.38x | 3.42x | 2.10x | 3.53x | 1.40x | 1.42x | 0.24x | 0.35x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 5.19M | 5.05M | 4.8M | 3.87M | 11.91M | 10.89M | 8.47M | 5.8M | 309K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 4.31M | 4.01M | 3.43M | 3.41M | 0 | 2.56M | 2.29M | 2.02M | 272K |
Other Non-Current Liabilities | 874.31K | 1.04M | 1.38M | 458K | 11.91M | 8.33M | 6.18M | 3.79M | 37K |
Total Liabilities | 10.57M | 8.93M | 7.01M | 8.94M | 20.24M | 17.61M | 16.03M | 31.6M | 14.36M |
Total Debt | 10K | 84K | 0 | 0 | 0 | 1.84M | 1.8M | 634K | 396K |
Net Debt | -14.44M | -5.87M | -5.43M | -8.76M | -27.59M | -5.52M | -3.44M | -1.02M | -3.95M |
Debt / Equity | 0.00x | 0.00x | - | - | - | 0.10x | 0.15x | - | - |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | - | - | -3.83x | - | - | -12129.42x | - | - | - |
Total Equity | 25.34M▲ 0% | 19.24M▼ 24.1% | 14.2M▼ 26.2% | 14.13M▼ 0.5% | 37.85M▲ 168.0% | 18.27M▼ 51.7% | 12.05M▼ 34.1% | -10.02M▼ 183.1% | -8.3M▲ 17.1% |
Equity Growth % | -25.33% | -24.06% | -26.23% | -0.49% | 167.97% | -51.72% | -34.06% | -183.13% | 17.13% |
Book Value per Share | 259.52 | 190.59 | 118.28 | 92.65 | 160.79 | 68.96 | 32.69 | -20.89 | -7.58 |
Total Shareholders' Equity | 25.34M | 19.24M | 14.2M | 14.13M | 37.85M | 18.27M | 12.05M | -10.02M | -8.3M |
Common Stock | 193.77M | 31.58M | 36.64M | 48.78M | 80.29M | 84.48M | 97.45M | 101.64M | 123.05M |
Retained Earnings | -170.96M | -14.64M | -24.95M | -36.19M | -44.2M | -68.62M | -89.08M | -115.13M | -134.83M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.93M | 1.84M | 2.04M | 1.07M | 1.76M | 2.41M | 3.68M | 3.48M | 3.1M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KZIA Cash Flow Statement
Kazia Therapeutics Limited (KZIA) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.43M | -8.66M | -6.71M | -8.81M | -9.11M | -22.76M | -15.16M | -9.58M | -13.28M |
Operating CF Margin % | -130.11% | -66074.15% | -429009.58% | -891.6% | -60.01% | -227620% | -2730810.81% | -415.12% | -31614.29% |
Operating CF Growth % | 4.55% | 24.26% | 22.48% | -31.22% | -3.42% | -149.83% | 33.42% | 36.78% | -38.59% |
Net Income | -10.67M | -6.04M | -10.27M | -12.47M | -8.42M | -25.01M | -20.46M | -26.78M | -20.7M |
Depreciation & Amortization | 1.41M | 1.55M | 1.08M | 1.08M | 1.26M | 1.87M | 1.87M | 1.87M | 934K |
Stock-Based Compensation | 517K | 165K | 246K | 262K | 637K | 1.68M | 1.16M | 533K | 653K |
Deferred Taxes | 3.51M | 3.97M | 1.81M | 168K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.33M | -9.84M | 62K | 474K | 3M | -2.15M | -2.05M | 4.79M | 8.85M |
Working Capital Changes | -4.02M | 1.54M | 353K | 1.67M | -5.59M | 862K | 4.33M | 10M | -3.01M |
Change in Receivables | -4.02M | 1.72M | 825K | 358K | -5.03M | -7K | 3.45M | 5K | 3.8M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -7.12M | 150K | 2.36M | 0 | 0 | -2.37M | 0 | 0 | 0 |
Capital Expenditures | -11.65K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 0.13% | - | - | - | - | - | - | - | - |
Acquisitions | -7.1M | 0 | 0 | 0 | 0 | -2.37M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -8.6K | 150K | 2.36M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -17.66K | 0 | 3.82M | 12.14M | 28.11M | 3.73M | 12.97M | 5.99M | 15.98M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 405K | 0 |
Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -18K | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 1.18M |
Net Change in Cash | -19M▲ 0% | -8.5M▲ 55.3% | -522K▲ 93.9% | 3.33M▲ 737.9% | 18.82M▲ 465.3% | -20.23M▼ 207.5% | -2.12M▲ 89.5% | -3.58M▼ 69.1% | 2.69M▲ 175.0% |
Free Cash Flow | -11.45M▲ 0% | -8.66M▲ 24.3% | -6.71M▲ 22.5% | -8.81M▼ 31.2% | -9.11M▼ 3.4% | -22.76M▼ 149.8% | -15.16M▲ 33.4% | -9.58M▲ 36.8% | -13.28M▼ 38.6% |
FCF Margin % | -130.25% | -66074.15% | -429009.58% | -891.6% | -60.01% | -227620% | -2730810.81% | -415.12% | -31614.29% |
FCF Growth % | 8.47% | 24.33% | 22.48% | -31.22% | -3.42% | -149.83% | 33.42% | 36.78% | -38.59% |
FCF per Share | -117.24 | -85.79 | -55.95 | -57.79 | -38.70 | -85.89 | -41.12 | -19.98 | -12.12 |
FCF Conversion (FCF/Net Income) | 1.07x | 1.43x | 0.65x | 0.71x | 1.08x | 0.91x | 0.74x | 0.36x | 0.64x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KZIA Key Ratios
Kazia Therapeutics Limited (KZIA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -30.81% | -36.01% | -27.09% | -61.43% | -88.05% | -32.4% | -89.14% | -134.97% | -2634.33% | - |
| Return on Invested Capital (ROIC) | -4002.89% | -143.04% | -77.2% | -56.8% | -129.54% | -61.21% | -165.51% | -169.41% | - | - |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -296.29% | -121.42% | -46071.1% | -656230.03% | -1261.75% | -55.46% | -250140% | -3687419.82% | -1160.23% | -49290.48% |
| Debt / Equity | 0.00x | 0.00x | 0.00x | - | - | - | 0.10x | 0.15x | - | - |
| Interest Coverage | - | - | - | -3.83x | - | - | -12129.42x | - | - | - |
| FCF Conversion | 0.99x | 1.07x | 1.43x | 0.65x | 0.71x | 1.08x | 0.91x | 0.74x | 0.36x | 0.64x |
| Revenue Growth | 4474.16% | 115.87% | -99.85% | -88.06% | 63038.02% | 1436.57% | -99.93% | -94.45% | 415755.86% | -98.18% |
Related:KZIA Dividend History·KZIA Revenue History·KZIA Price History·KZIA P/E History·KZIA Financial Ratios·KZIA Institutional Holders
KZIA Frequently Asked Questions
Kazia Therapeutics Limited (KZIA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kazia Therapeutics Limited (KZIA) reported $2.5M in revenue for fiscal year 2025. This represents a 87% decrease from $19.3M in 1999.
Kazia Therapeutics Limited (KZIA) saw revenue decline by 98.2% over the past year.
Kazia Therapeutics Limited (KZIA) reported a net loss of $47.2M for fiscal year 2025.
Dividend & Returns
Kazia Therapeutics Limited (KZIA) had negative free cash flow of $13.8M in fiscal year 2025, likely due to heavy capital investments.